An isocratic reversed-phase high-pressure liquid chromatographic method for the determination of six components of the teicoplanin complex in biological fluid was developed. By using fluorescence detection after precolumn derivatization with fluorescamine, the assay is specific and highly sensitive, with reproducibility studies yielding coefficients of variation ranging from 1.5 to 8.5% (at 5 to 80 ,ug/ml). Response was linear from 2.5 to 80 ,ug/ml (r = 0.999); the recovery from spiked human serum was 76%. An external quality control was performed to compare this high-pressure liquid chromatographic method (H) with a standard microbiological assay (M); no significant deviation from slope = 1 and intercept = 0 was found by regression analysis (H = 1.03M -0.45; n = 15).
Teicoplanin is a new glycopeptide antibiotic produced by Actinoplanes teichomyceticlls (1, 10) which shows appreciable activity against staphylococci and streptococci (9, 13) , corynebacteria (7) , listeria (8) , and clostridia (Y. Glupczynski, M. Labbe, F. Orokaert, and E. Yourassowsky, Letter, Eur. J. Clin. Microbiol. 3:50-51, 1984 ). It appears to inhibit cell wall biosynthesis in gram-positive organisms by interfering with peptidoglycan polymerization (12) . Pharmacokinetic investigations showed a multiexponential concentration in blood-versus-time profile with elimination halflives of 45 to 50 h (13) , which is 6 to 10 times longer than that of vancomycin. In a recent review, Williams and Gruneberg (14) reported on the in vitro and in vivo activity, pharmacology, and toxicology of teicoplanin. They recommended that levels in serum be monitored until the safety of this potentially valuable antibiotic is assured. Furthermore, they recommended additional studies to examine penetration of teicoplanin into various body fluids and to assess its therapeutic efficacy. Toxicity must be avoided in ongoing clinical trials by reasonable dosage recommendations formulated on the basis of concentrations in serum. Consequently, an accurate, sensitive, and specific assay for the determination of teicoplanin is needed.
The development of a high-pressure liquid chromatographic (HPLC) assay is difficult, since teicoplanin is a mixture of several related substances. The structures of its main components, A2-1, A2-2, A2-3, A2-4, and A2-5, and of the pseudoaglycones, A3-1 and A3-2, have recently been elucidated (2, 3, 6) . Several minor constituents, designated A2-la, A2-lb, A2-1c, A2-ld, A2-le, A2-3a, and A2-5a, were also detectable by use 
RESULTS
Typical chromatograms of spiked and blank serum samples are shown in Fig. 1 . The retention times were 10.2, 13.7, 15.7, 17.9, 23.2, and 25.4 min for active teicoplanin components A2-1, A2-2, A2-3, A2-3a, A2-4, and A2-5, respectively, with <1% variation over 24 h (n = 20). The underivatized components previously have been separated by use of a semipreparative gradient chromatography adapted from the method of Borghi and co-workers (4) . Partially purified compounds were derivatized and analyzed separately to permit unambiguous identification of the observed peaks (B. Joos and R. Luthy, submitted for publication).
A calibration curve, constructed by plotting peak area against concentrations of serum standards containing graded amounts of teicoplanin, showed a linear response from 2.5 to 80 jig/ml, with a correlation coefficient of 0.999. Recovery was 76% from spiked human serum (2.5 to 80 [Lg/ml) compared with a similar standard curve resulting from teicoplanin solutions prepared in water. The limit of detection was approximately 0.5 Rg/ml. For six replicate measurements each made at 80, 40, 20, 10, and 5 p.g/ml, the variability (coefficient of variation of total area) was 1.5, 2.4, 1.5, 4.1, and 8.5%, respectively. No loss of fluorescence was observed in prepared samples stored for >24 h at room temperature.
The accuracy of the method was tested by comparing the HPLC results for coded serum samples, which ranged in concentration from 5 to 25 Fg/ml, with the results obtained from a microbiological assay. Quality control samples were analyzed in an external laboratory (Gruppo Lepetit S.p.A., Milan, Italy) with Bacillus subtilis as the test organism (5) . The correlation between the two methods is shown in Fig. 2 . Regression analysis was performed by the procedure of Passing and Bablok (11) . The slope of the regression line was 1.030 (95% confidence interval from 0.900 to 1.130), and the intercept was -0.445 (confidence limits, -1.865 and 0.840).
The specificity of the assay was evaluated by analyzing aqueous solutions of various drugs at high concentrations.
Over 50 antimicrobial agents were tested and shown not to interfere with this HPLC assay at levels exceeding their usual therapeutic range. These included six aminoglycosides, tested at >100 p.g/ml (amikacin, gentamicin, neomycin, netilmicin, streptomycin, and tobramycin); 11 penicillins, tested at >300 .Lg/ml (amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, flucloxacillin, mezlocillin, penicillin G, penicillin V, piperacillin, and ticarcillin); 13 cephalosporins, tested at >300 [Lg/ml (cefamandole, cefazolin, cefoperazone, cefotaxime, cefotiam, cefoxitin, cefsulodin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalothin, and moxalactam); four other beta-lactams, tested at >300 p.g/ml (aztreonam, clavulanic acid, imipenem, and sulbactam); two glycopeptides, tested at >300 [Lg/ml (ristocetin and vancomycin); seven quinolones, tested at >100 jig/ml (cinoxacin, ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and pipemidic acid); and nine other antimicrobial agents, tested at >300 p.g/ml (chloramphenicol, clindamycin, erythromycin, miconazole, ornidazole, rifampin, sulfamethoxazole, thiamphenicol, and trimethoprim). Interfering peaks found in one sample of human urine prohibited quantitation of the components A2-1 and A2-3a, at least at low concentrations. Nevertheless, determination of the major compounds of teicoplanin in urine appears feasible.
The flexibility of this method was examined by testing some potentially useful modifications. The speed of the assay could be increased by higher contents of butanol or acetonitrile in the mobile phase. No significant loss of resolution was observed after addition of approximately 0.5% more butanol, which decreased the run time by 50%.
Moreover, the limit of detection could be decreased many times by injecting larger volumes. A serum sample from a patient containing approximately 3.6 1Lg of teicoplanin per ml was tested at seven different injection volumes (10, 20, 40, 60, 80, 100, and 150 jil). No significant distortion of the chromatograms was observed, and the response was perfectly linear.
DISCUSSION
The reversed-phase HPLC method described above is accurate, reproducible, specific, and highly sensitive. Sample preparation is simple, and precolumn derivatization with fluorescamine facilitates isocratic separation and determination of teicoplanin components A2-1, A2-2, A2-3, A2-3a, A2-4, and A2-5 in human serum. The classification of these different components of the teicoplanin complex is in agreemept with the nomenclature of other investigators (data not shown).
Only small sample volumes (100 [L) are required, and the limit of detectability (0.5 ,ug/ml) is well below the usual therapeutic concentrations (5 to 50 p.g/ml). By measuring fluorescence, absolute amounts of teicoplanin above approximately 670 pg are detectable. This represents an improvement in sensitivity by a factor of 100 to 1,000 compared with UV absorbance.
Among the drawbacks of the assay are low recovery and lack of an internal standard. The reduced recovery is attributable to the influence of serum proteins or to incomplete reaction with the derivatizing agent. Therefore, serum standards must be used for calibration. Special attention must be paid to absolute injection volumes, since an internal standard was not included.
Nevertheless, this method has the potential for several helpful modifications to meet particular requirements with regard to speed, sensitivity, simplicity, and specimens. A new evaluation of the assay performance will be required, however, for such alterations. (i) The duration of analysis, under the conditions described, was 30 min per sample. When a higher rate is desirable for routine use, retention times may be decreased easily by a modification of the mobile phase. (ii) The assay was designed to measure therapeutic concentrations ranging from 5 to 50 p.g/ml. When injection volumes of 20 plI are used, the lower limit of detectability is 0.5 pg/ml for the main component A2-2, whereas the minor components are difficult to quantitate at total teicoplanin concentrations below 5 p.g/ml. Consequently, with injection volumes of 150 ,ul, the detection limit will be at approximately 0.07 ,ug/ml. Measurement 
